FIG. 1

CH4 — CεmX — migis

SVNPGLAGGSAQSQRAPDRVLCHSGQQQGLPRAAGGSVPHPRCHCGAGRADWPGPPELDV

P1 SVNPGLAGGSAQSQRAPDRVL

P2 HSGQQQGLPRAAGGSVPHPR

P3 GAGRADWPGPPELDV

	5H2	mIgG	a20	1G2	3A6	3H11	6H12	18A11	1A8	4B12	23B8	26H2
P1	-	-	-	-	-	-	-	-	-	+	-	-
P2	-	-	-	-	-	-	-	-	-	-	-	+
P3	-	-	+	+	+	+	+	+	+	-	+	-
mIgE.Fc$_L$	+	-	+	+	+	+	+	+	+	+	+	+
mIgE.Fc$_S$	+	-	-	-	-	-	-	-	-	-	-	-
IgE	+	-	-	-	-	-	-	-	-	-	-	-

FIG. 2



5H2
a20
1A8
1G2
3A6
3H11
4B12
6H12
18A11
23B8
26H2
CHO mIgE.Fc$_L$
CHO mIgE.Fc$_S$
Ramos mIgE.Fc$_L$
Ramos mIgE.Fc$_S$
Count
FITC-A

FIG. 3A



ca20
c4B12
c26H2
Omalizumab
Rituximab
cBAT123
cB1-8
hIgG
% of target cell killing
100
80
60
40
20
0
3.125
6.25
12.5
25
50
E/T ratio

FIG. 3B



ca20
c4B12
c26H2
Omalizumab
Rituximab
cBAT123
cB1-8
hIgG
% of target cell killing
100
80
60
40
20
0
0.0001
0.001
0.01
0.1
1
10
Antibody Concentration μg/ml

FIG. 4A



ca20
c4B12
c26H2
omalizumab
cBAT123
cB1-8
% Annexin V+/PI-
100
80
60
40
20
0
0
0.0625
0.125
0.25
0.5
1
2
Antibody Concentration ug/ml

FIG. 4B




Conti Ig
0.89%
ca20
0.96%
c26H2
32.82%
c4B12
23.96%
omalizumab
21.15%
PI

FIG. 4C


hIgG
cBAT123
cB1-8
ca20
cAB12
c26H2
omalizumab
PARP (116 kDa)
Cleaved PARP (89 kDa)
Caspase 3 (35 kDa)
Cleaved Caspase 3 (17 kDa)
Cleaved Caspase 3 (15 kDa)
Actin

Light chain

```
          1    .    10    .    20    .  abcde 30    .    40    .    50    .    60
4B12      DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPD
KV2       DIVMTQTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQKPGQSPQLLIYEVSSRFSGVPD
Replace    IV        S TP QP                                    Q
                .   70    .   80    .   90    .  100    .
4B12      RFSGSGSGTDFTFKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIKR
KV2       RFSGSGSGTDFTLKISRVEAEDVGVYYCMQGIQLPPTFGGGTKVEIKR
Replace              L         V                    V
```

Heavy chain

```
          1    .    10    .    20    .    30   .a   40    .    50    .    60    .
4B12      DVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMGSISYSGITGYNPSLKS
HV4       QVQLQESGPGLVKPSETLSLTCTVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKS
Replace   Q              ET       S                P  KG   I
             70    .   80  abc  .    90    .  100    .  110
4B12      RISVTRDTSKNQFFLQLNSVTTEDTATYYCARMGYDGLAYWGHGTTVTVSA
HV4       RVTISVDTSKNQFSLKLSSVTAADTAVYYCAR--------YWGQGTLVTVSS
Replace    VTISV       S K S   AA   V                Q  L    S
```

FIG. 5